Type 2 diabetes (T2D) is a chronic metabolic disorder, which was also found to involve a series of inflammatory disorders, including accumulation of macrophages and T cells in the adipose tissue, increased proinflammatory cytokine production, shifting of macrophage composition toward M1-type, and skewing of peripheral blood T cells toward IL-17 productions. However, these studies were primarily conducted in obese mouse models and/or human subjects with higher BMI, and may not reflect the role of the immune system in non-obese T2D pathogenesis. Here, we examined T cell and monocyte cytokine expression and function in both non-obese and obese T2D patients. We found that IFN-g production by circulating T cells were increased in both non-obese and obese T2D subjects, while IL-17 is only upregulated in obese T2D subjects. Also, circulating monocytes from obese T2D subjects had significantly higher IL-6 production than their counterparts in non-obese T2D subjects. Moreover, monocytes from non-obese T2D subjects could support IFN-g but not IL-17 production in vitro, while that from obese T2D subjects supported both IFN-g and IL-17 production. Together, our results revealed that the role immune system plays in T2D pathogenesis is more complicated than previously thought, and is affected by the person's BMI.
Introduction
Type 2 diabetes (T2D) is a chronic metabolic disorder that involves multiple complications resulted from the accumulation of blood glucose due to insufficient insulin production by beta cells and/or decrease in insulin sensitivity in muscle, fat and liver cells. The increasing incidence of T2D is primarily associated with rising obesity levels caused by high fat diets and sedentary lifestyles in genetically predisposed individuals. 1 Recently, the role of inflammatory immune responses and its complications in the pathogenesis of T2D are being increasingly recognized. The underlying mechanisms of defective insulin secretion and response include glucotoxicity, lipotoxicity, oxidative stress, endoplasmic reticulum stress, alterations of the gut microbiota, endocannabinoids, and the formation of amyloid deposits in the islets, all of which are either directly associated with pathways in the immune system, or indirectly affected by immune activation. 2, 3 In particular, the proinflammatory phenotype adopted by islet-resident macrophages was found to induce islet dysfunction by production of IL-1β and subsequent induction of IL-6, IL-8, tumor necrosis factor (TNF), and CCL2, which lead to further recruitment of macrophages and other immune cell types. [4] [5] [6] [7] [8] The accumulation of macrophages in adipose tissues was also thought to contribute to insulin resistance and prediabetes. Studies have found that macrophages tended to accumulate in the adipose tissues of obese mice, and have a classical activated proinflammatory M1 phenotype, with increased TNF and reduced IL-10 production. 9, 10 Additionally, monocytes from T2D patients constitutively secrete elevated levels of proinflammatory cytokines IL-6, IL-8, TNF-α, and IL-1β. 11 T cell accumulation in obese adipose tissue was found in parallel with macrophages. 12 Among them, elevated regulatory T (Treg) cell frequency in lean but not obese mice is thought to alleviate insulin resistance by suppressing inflammation, while Th1 cells and CD8 + T cells are thought to contribute to insulin resistance. 13, 14 Proinflammatory macrophage in obese adipose tissue might negatively impact insulin resistance by shifting the T cell balance away from regulatory T cells, but the precise dynamics in macrophage-T cell interactions require more study. It was found that skewing of T cell composition toward the Th17 phenotype in the peripheral blood of obese diabetic patients required support by macrophages. 15 These previous studies on macrophage and T cell involvement in T2D pathogenesis were primarily done in obese patients and obese mouse models. In individuals of European descent, T2D is strongly associated with obesity with average body mass index (BMI) of 30 kg/m 2 . In individuals of Chinese descent, however, T2D patients were found to have a much lower average BMI of 25 kg/m 2 . 16, 17 Moreover, obesity accounted for 80-100% of T2D cases in people of European or African descents while in people of East Asian descents, obesity accounted for only 30% of all T2D cases. Lean/nonobese T2D patients were also found to have a significantly higher mortality rate than obese T2D patients. 18 These observations raised the question of whether studies using obese mice and human subjects with higher BMI truly reflect the role of macrophages in mediating T2D pathogenesis in non-obese diabetic individuals.
To improve our understanding in the involvement of the immune system in non-obese T2D patients, we examined T cell and monocyte responses in nonobese diabetic patients. We found that T cells in non-obese T2D subjects had significantly upregulated IFN-g but not IL-17 production, and T cells in obese T2D subjects expressed higher levels of IFN-g and IL-17 than non-obese T2D subjects. Unlike those in obese diabetic subjects, monocytes in nonobese diabetic subjects had significantly less IL-6 production and could support T cell IFN-g but not IL-17 production from T cells. Together, our data demonstrated that monocytes in non-obese diabetic individuals had different T cell-stimulating roles from those in obese diabetic individuals.
Methods

Subjects
All samples and procedures were approved by the Institutional Review Board of General Hospital of Guangzhou Military Command of PLA and were collected and processed in accordance with the Declaration of Helsinki. A total of 12 non-obese non-diabetic, 12 obese non-diabetic, 17 non-obese diabetic, and 15 obese diabetic subjects were recruited and written informed consent were obtained from all subjects. All non-diabetic subjects were healthy without concurrent inflammatory diseases (aside from obesity in obese non-diabetic subjects) for more than 3 weeks before the time of sample collection. All donors were non-smokers. Subjects with possibility of chronic exposure of secondhand smoking were excluded. A lower BMI cutoff standard for the Chinese population is used to distinguish between obese and non-obese subjects, since the risk of obesity-related diseases are elevated in Chinese individuals with lower BMI than individuals of European descent. [19] [20] [21] The body fat percentage (BF%) of study subjects was measured using a previously described method. 22 Diabetic subjects were diagnosed with type 2 diabetes but were not on medication at the time of sample collection. Age, sex, BMI, and other demographic characteristics are summarized in Table 1 .
Sample collection and processing
Peripheral blood samples were collected by venipuncture. Peripheral blood mononuclear cells (PBMCs) were obtained by a standard Ficoll-Hypaque centrifugation protocol and frozen immediately in fetal bovine serum (FBS) plus 10% DMSO at −150°C until use.
Luminex assay
Purified T cells were negatively selected by using Human T cell Enrichment Kit (Stemcell), and then cultured at the bottom of a 96-well 1.0 µm pore size transwell plate (Corning) at 10 5 cells per well, in 200 µL media, with or without 3 µg/mL anti-CD3 antibody. Anti-human IFN-g, IL-4, IL-10, and IL-17 antibodies and capture beads (Millipore) were placed at the top. After 12 h, beads were harvested and measured by Luminex assay according to manufacturer's instructions. For monocyte cytokine expression measurement, monocytes were negatively selected by using Human Monocyte Enrichment Kit (Stemcell) and cultured without or with heat-killed E. coli (Invivogen), following the same procedures as the Luminex assay for T cells. Anti-human TNF-a, IL-6, and IL-10 antibodies (Millipore) were used.
T cell-monocyte coculture
Biotinylated anti-human CD14 monoclonal antibody (BD) were added at 5 µg per million PBMCs and incubated for 30 min in 4°C, and washed twice in culture media, after which anti-CD14 bound monocytes were separated from PBMCs with Biotin Positive Selection Kit (Stemcell) using manufacturer's protocol. 10 5 cells of CD14-depleted PBMCs and anti-CD14 bound monocytes, alone or added together in 1:1 ratio, were cultured in 24 h, in 200 µL media alone or with 3 µg/mL anti-human CD3 antibody (BD). Supernatant was then obtained and prepared for IFN-g and IL-17 concentration measurement using Human IFN-g ELISA and Human IL-17 ELISA kits (Abcam) according to manufacturer's protocols.
Statistical analyses
All data were shown as mean +/-standard deviation. Data normality was tested by Shapiro-Wilk test. For normally distributed populations, Student's t test or ordinary ANOVA followed by Tukey's multiple comparisons test were used for comparisons between two or multiple groups, respectively; otherwise, non-parametric tests (Wilcoxon test for two groups; Kruskal-Wallis test and Dunn's test for multiple groups) were used. Correlation analyses were done using Pearson correlation test. Differences were considered significant at P <0.05. All statistical analyses were done using Prism 6 software (GraphPad).
Results
Non-obese diabetic subjects expressed cytokine profile different from that of obese diabetic individuals
Most previous studies demonstrating the linkage between diabetes and inflammation were conducted using obese mouse models and overweight and/or obese human subjects. To distinguish between the effects of diabetes and obesity, we recruited four different groups, including 12 non-obese non-diabetic All numerical values were shown as median (range). A1c, hemoglobin A1c; BF%, body fat percentage; BMI, body mass index; N.S., not significant.
(non-obese ND), 12 obese non-diabetic (obese ND), 17 non-obese diabetic (non-obese T2D), and 15 obese diabetic (obese T2D) subjects. Peripheral blood mononuclear cells (PBMCs) were obtained from all subjects. The demographic and clinical characteristics of study subjects were summarized in Table 1 .
We first examined the cytokine expression profile of circulating leukocytes in study subjects. Previously, T2D patients exhibited peripheral T cell cytokine expression bias toward higher IFN-g and IL-17 production, while IL-4 level was unchanged from that in healthy subjects. 15 We found that very little IFN-g was expressed by resting T cells in nonobese ND subjects, while higher IFN-g expression was found in obese ND, non-obese T2D, and obese T2D subjects ( Figure 1a ). T cells from obese T2D subjects also expressed higher levels of IFN-g than those from obese ND and non-obese T2D subjects. After anti-CD3 stimulation, both non-obese and obese T2D subjects had higher IFN-g expression from T cells than non-obese ND subjects ( Figure  1b ). Again, obese T2D subjects had higher IFN-g secretion than obese ND and non-obese T2D subjects. No significant differences were observed in IL-4 production between different study groups. The production of IL-10 by T cells at resting state was higher in obese ND subjects than that in nonobese ND, non-obese T2D, and obese T2D subjects. After anti-CD3 stimulation, non-obese ND subjects had higher IL-10 expression than nonobese T2D and obese T2D subjects. In terms of IL-17 production by T cells, we observed higher IL-17 secretion in obese T2D subjects than that in non-obese ND and non-obese T2D subjects, both under unstimulated condition and after stimulation by anti-CD3 antibody. Together, these findings demonstrated that T cells in T2D subjects exhibited a more pro-inflammatory phenotype. In addition, we observed that IFN-g and IL-17 production by T cells were different between non-obese T2D and obese T2D patients.
Monocytes from non-obese T2D subjects expressed lower levels of IL-6 than those from obese T2D subjects
Macrophages are important antigen-presenting cells that also function to modulate T cell responses and regulate Th1, Th17, and Treg differentiation by expressing various costimulatory or inhibitory transmembrane molecules and secreted cytokines. 23, 24 Classically activated macrophages with a proinflammatory phenotype (M1-type, expressing TNF) accumulated in the adipose tissue of obese mice, were relatively upregulated, compared to alternatively activated M2-type macrophages (expressing IL-10), and were thought to exacerbate local inflammation and insulin resistance. 10, 25 Activated M1-type monocytes were also found to evoke Th1 and Th17 responses. 26, 27 IL-6 secreted by monocytes and macrophages was shown to support IL-17 production and Th17 bias in obese mice and T2D humans. 15, [28] [29] [30] Stimulation of macrophages by pathogen-associated molecular pattern (PAMP) could significantly upregulate cytokine expression. 23 We then investigated monocyte functions in non-obese T2D and obese T2D subjects. The expressions of TNF-a, IL-6, and IL-10 were examined (Figure 2a and b ). We found that monocytes from non-obese T2D subjects had significantly less IL-6 secretion than those from obese T2D subjects, both directly ex vivo and after stimulation by E. coli. No significant differences in TNF-a and IL-10 secretion were found between non-obese T2D and obese T2D patients. We also examined the monocytes in ND individuals, and found that IL-6 production by monocytes was significantly upregulated in obese ND subjects compared to non-obese ND subjects (Figure 2e ).
Lower IL-6 by monocytes is correlated with lower IL-17 production by T cells in T2D subjects
Since monocytes were shown to induce Th17 priming through IL-6-dependent antigen-presenting function, we next examined the correlation between IL-6 production by monocytes and IL-17 production by autologous T cells. 28 We found that in both non-obese T2D subjects and obese T2D subjects, the level of IL-17 secreted by T cells was positively correlated with IL-6 secretion by monocytes (Figure 2d and e). No correlation between IL-17 and other monocyte-secreted cytokines was found (data not shown).
Monocytes from non-obese T2D subjects supported IFN-g but not IL-17 secretion in vitro
The correlation between IL-6 production in monocytes and IL-17 in T cells could be due to increased inflammatory cytokine production in a subset of T2D patients in general, or increased IL-6 in monocytes could actively support IL-17 expression. To examine whether monocytes from nonobese T2D subjects could support IL-17 secretion in T cells, as was found previously in obese subjects, 15 we used CD14 expression to separate monocytes from other peripheral blood mononuclear cells. CD14-positively selected monocytes were also obtained and added back to some of the cell cultures. We found that CD14-depleted PBMCs (CD14 -) had significantly lower IFN-g production than CD14-depleted PBMCs with monocytes (CD14 -+M) in non-obese T2D subjects, after anti-CD3 stimulation (Figure 3a) . The source of IFN-g in CD14 -+M culture was likely from CD14-depleted PBMCs instead of monocytes, since the purified monocyte (M alone) culture contained significantly lower levels of IFN-g than both the CD14culture and the CD14 -+M culture. In terms of IL-17 production in non-obese T2D subjects, no significant differences between CD14and CD14 -+ M cultures were found. Again, the source of IL-17 in seems to be from CD14-depleted PBMCs, since the purified monocyte (M alone) culture contained significantly lower levels of IL-17 than both the CD14culture and the CD14 -+M culture. On the other hand, the replacement of monocytes in obese T2D subjects was found to increase the secretion of both IFN-g and IL-17 by PBMCs (Figure 3b ). To rule out the possibility that CD14-positive selection had altered monocyte function, we also compared IL-6 production between CD14-positively selected monocytes and negatively selected monocytes from previous experiments. No significant differences were observed in terms of IL-6 production between CD14-positively selected monocytes and negatively selected monocytes. Together, these data demonstrated that unlike monocytes from obese T2D subjects, monocytes from non-obese T2D subjects were able to support IFN-g production but not IL-17 production in vitro.
Addition of IL-6 improved monocyte support of IL-17 secretion
We wondered whether the lack of monocyte-mediated support of IL-17 production in non-obese T2D subjects was due to reduced level of IL-6 secretion. In a separate experiment, we added various concentrations of IL-6 in CD14 -+ M culture in nonobese subjects. We found that 2 µg/mL IL-6 could significantly increase IL-17 concentration in culture ( Figure 4a ). Further addition to 10 µg/mL IL-6 did not further increase IL-17 concentration. We also found that addition of 2 µg/mL IL-10 in culture had lowered average IL-17 concentration, but the results were not significant. Previously, we found that IL-6 and IL-10 were both upregulated when monocytes were stimulated with E. coli. Therefore, we pretreated monocytes with E. coli before addition into the coculture. Interestingly, we found that monocyte pretreatment with E. coli had significantly downregulated IL-17 in culture.
We repeated this experiment in obese T2D patients, and found that similar to the observation in non-obese T2D subjects, addition of IL-6 had significantly increased IL-17 concentration in the culture supernatant (Figure 4b) . Different from the result in non-obese subjects, the addition of IL-10 or pre-treatment with E. coli, however, did not downregulate IL-17 production.
Discussion
The role of the immune system in promoting T2D is being increasingly recognized. 3, 31 In particular, the accumulation of M1-type macrophages in the adipose tissue of obese subjects was proposed to contribute to insulin resistance by producing IL-1β, which induced various other cytokines and chemokines, including TNF, IL-6, and CCL2, which in turn recruited other immune cells and exacerbated inflammation in a vicious cycle. 8, 32, 33 Moreover, IL-6 production by monocytes directly contributed to the skewing of circulating T cell composition toward Th17 phenotype. 15 These studies, however, utilized obese animal models and human subjects. Whether the findings were applicable in T2D subjects with lower BMI is currently unclear. To solve this issue, in this study we grouped T2D subjects into non-obese and obese groups by their BMI. We first found a series of differences between non-obese T2D subjects and obese T2D subjects. Although both non-obese T2D and obese T2D subjects had elevated IFN-g production than non-obese ND subjects, obese-T2D subjects had significantly higher IFN-g than non-obese T2D subjects. Moreover, the CD14-depleted PBMCs with anti-CD14 bound monocytes replaced were stimulated with anti-CD3 antibody for 24 h and the concentration of IL-17 in culture was measured by ELISA. In some cocultures, various concentrations of recombinant IL-6 or IL-10 were added at the beginning of incubation. In the E. coli-pretreated monocyte culture, anti-CD14 bound monocytes were first pre-incubated with heat-killed E. coli for 12 h prior to adding into the coculture. N = 5 for each experiment. *P <0.05. **P <0.01.
IL-17 production was significantly elevated in obese T2D subjects but not in non-obese T2D subjects. Since antigen-presenting cells are known to modulate immune responses, we also examined cytokine production by monocytes, and found that obese T2D subjects had significantly higher levels of IL-6 production by monocytes, both in unstimulated condition and after stimulation with E. coli. Moreover, we found that the level of IL-6 secretion by monocytes was positively correlated with the IL-17 secretion by autologous T cells, both in obese and non-obese T2D subjects. We then found that non-obese T2D monocytes supported IFN-g but not IL-17 production by anti-CD3 activated cells, while obese T2D monocytes supported both. Addition of IL-6 in coculture increased IL-17 secretion in non-obese T2D subjects. Together, our data demonstrated that the immunostimulatory role of monocytes in non-obese T2D patients were different from those in obese T2D patients.
Interestingly, E. coli-pretreated monocytes had significantly reduced IL-17 production in nonobese T2D patients but did not affect IL-17 production in obese T2D subjects. Since both IL-6 and IL-10 were upregulated by E. coli-stimulation, the reduction of IL-17 in non-obese T2D might be induced by IL-10-mediated suppression. Such effects were not observed in obese T2D subjects, further illustrating the regulation of monocytes directly by obesity. In line with this, we found that IL-6 production was upregulated in obese ND subjects compared to non-obese ND subjects, in the absence of T2D development.
Aside from participating in inflammatory responses, IL-6 has pleiotropic effects on glucose metabolism. In healthy individuals, IL-6 infusion was found to increase insulin-stimulated glucose disposal. 34 It is a myokine released by muscle fibers during physical activity and was thought to affect muscle metabolism by increasing fatty acid oxidation and increasing basal and insulin stimulated glucose uptake. 34, 35 In obese individuals, it appears that the proinflammatory role IL-6 takes over and may exacerbate insulin resistance through increasing inflammation. 2 Also, the location and timing of IL-6 release might result in different effects, since IL-6 in adipose tissues were shown to increase liver expression of SOCS3, a protein that induces hepatic insulin resistance. 36 In our study, we observed that circulating monocytes from non-obese T2D subjects had less IL-6 secretion than their counterparts in obese T2D subjects and did not support IL-17 skewing in vitro. Previously, Th17 cells and IL-17 have been implicated in the pathogenesis of various chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, and multiple sclerosis. 37 Our results suggested the possibility that monocytes in non-obese T2D individuals may have less proinflammatory effects in the pathogenesis of T2D, which requires further experiments for validation.
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